ABRAXANE Approved For Advanced Breast Cancer Patient Treatment In Quebec

[News]

Abraxis BioScience, Inc. (NASDAQ:ABII), an integrated biotechnology company, announced the listing of ABRAXANE® for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) 100 mg in Quebec for the treatment of metastatic breast cancer with a recommendation from the Quebec Conseil du Médicament and approval from the Quebec Ministry of Health.

More... (http://www.medicalnewstoday.com/articles/155954.php)